The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Hassan Kahal, Ahmed Aburima, Tamas Ungvari, Alan S. Rigby, Anne M. Coady, Rebecca V. Vince, Ramzi A. Ajjan, Eric S. Kilpatrick, Khalid M. Naseem, Stephen Atkin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight. Methods: Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month - baseline) ± standard deviation. Results: Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41. No significant changes were noted in cIMT or RHI. Conclusions: Six months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3-4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.

Original languageEnglish
Article number14
JournalBMC Endocrine Disorders
Volume15
Issue number1
DOIs
Publication statusPublished - 2 Apr 2015
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Blood Platelets
Carotid Intima-Media Thickness
Obesity
Hyperemia
Weights and Measures
Therapeutics
Weight Loss
Isoprostanes
Selectins
P-Selectin
Liraglutide
Ultrasonography
Flow Cytometry
Triglycerides
Enzyme-Linked Immunosorbent Assay
Confidence Intervals
Inflammation
Control Groups
Serum

Keywords

  • cIMT
  • Liraglutide
  • Obesity
  • PCOS
  • Platelet function

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. / Kahal, Hassan; Aburima, Ahmed; Ungvari, Tamas; Rigby, Alan S.; Coady, Anne M.; Vince, Rebecca V.; Ajjan, Ramzi A.; Kilpatrick, Eric S.; Naseem, Khalid M.; Atkin, Stephen.

In: BMC Endocrine Disorders, Vol. 15, No. 1, 14, 02.04.2015.

Research output: Contribution to journalArticle

Kahal, Hassan ; Aburima, Ahmed ; Ungvari, Tamas ; Rigby, Alan S. ; Coady, Anne M. ; Vince, Rebecca V. ; Ajjan, Ramzi A. ; Kilpatrick, Eric S. ; Naseem, Khalid M. ; Atkin, Stephen. / The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. In: BMC Endocrine Disorders. 2015 ; Vol. 15, No. 1.
@article{ed56337f2fe641bcb3f576e926ae0816,
title = "The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls",
abstract = "Background: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight. Methods: Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month - baseline) ± standard deviation. Results: Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4{\%}) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95{\%} confidence interval = -0.14 - 0.26, P = 0.41. No significant changes were noted in cIMT or RHI. Conclusions: Six months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3-4{\%} weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.",
keywords = "cIMT, Liraglutide, Obesity, PCOS, Platelet function",
author = "Hassan Kahal and Ahmed Aburima and Tamas Ungvari and Rigby, {Alan S.} and Coady, {Anne M.} and Vince, {Rebecca V.} and Ajjan, {Ramzi A.} and Kilpatrick, {Eric S.} and Naseem, {Khalid M.} and Stephen Atkin",
year = "2015",
month = "4",
day = "2",
doi = "10.1186/s12902-015-0005-6",
language = "English",
volume = "15",
journal = "BMC Endocrine Disorders",
issn = "1472-6823",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

AU - Kahal, Hassan

AU - Aburima, Ahmed

AU - Ungvari, Tamas

AU - Rigby, Alan S.

AU - Coady, Anne M.

AU - Vince, Rebecca V.

AU - Ajjan, Ramzi A.

AU - Kilpatrick, Eric S.

AU - Naseem, Khalid M.

AU - Atkin, Stephen

PY - 2015/4/2

Y1 - 2015/4/2

N2 - Background: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight. Methods: Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month - baseline) ± standard deviation. Results: Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41. No significant changes were noted in cIMT or RHI. Conclusions: Six months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3-4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.

AB - Background: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight. Methods: Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month - baseline) ± standard deviation. Results: Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41. No significant changes were noted in cIMT or RHI. Conclusions: Six months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3-4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.

KW - cIMT

KW - Liraglutide

KW - Obesity

KW - PCOS

KW - Platelet function

UR - http://www.scopus.com/inward/record.url?scp=84926343937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926343937&partnerID=8YFLogxK

U2 - 10.1186/s12902-015-0005-6

DO - 10.1186/s12902-015-0005-6

M3 - Article

C2 - 25880805

AN - SCOPUS:84926343937

VL - 15

JO - BMC Endocrine Disorders

JF - BMC Endocrine Disorders

SN - 1472-6823

IS - 1

M1 - 14

ER -